Analysts See $-0.51 EPS for Quotient Limited (QTNT)

May 18, 2018 - By Marguerite Chambers

Quotient Limited (NASDAQ:QTNT) LogoInvestors sentiment increased to 1.93 in 2017 Q4. Its up 0.51, from 1.42 in 2017Q3. It increased, as 5 investors sold Quotient Limited shares while 10 reduced holdings. 7 funds opened positions while 22 raised stakes. 30.23 million shares or 41.49% more from 21.37 million shares in 2017Q3 were reported.
Millennium Mngmt Ltd stated it has 0% in Quotient Limited (NASDAQ:QTNT). California State Teachers Retirement Systems owns 42,400 shares. 2,022 are owned by Royal National Bank Of Canada. Citigroup Inc holds 0% of its portfolio in Quotient Limited (NASDAQ:QTNT) for 3,157 shares. Macquarie Group Inc Inc invested in 0% or 6,000 shares. Morgan Stanley holds 0% or 108,676 shares in its portfolio. International Grp invested in 18,011 shares. Blackrock Inc holds 1.20M shares. Moreover, Geode Limited Liability has 0% invested in Quotient Limited (NASDAQ:QTNT). Moreover, Ameriprise Financial has 0% invested in Quotient Limited (NASDAQ:QTNT). State Street owns 378,984 shares. Rhumbline Advisers has invested 0% in Quotient Limited (NASDAQ:QTNT). Moreover, Northern Tru Corp has 0% invested in Quotient Limited (NASDAQ:QTNT) for 235,893 shares. Bank & Trust Of America De holds 3,739 shares or 0% of its portfolio. Knott David M invested 0.19% in Quotient Limited (NASDAQ:QTNT).

Since February 21, 2018, it had 1 buying transaction, and 0 sales for $51,348 activity.

Analysts expect Quotient Limited (NASDAQ:QTNT) to report $-0.51 EPS on May, 28.They anticipate $0.18 EPS change or 26.09 % from last quarter’s $-0.69 EPS. After having $-0.47 EPS previously, Quotient Limited’s analysts see 8.51 % EPS growth. The stock increased 15.35% or $0.72 during the last trading session, reaching $5.41. About 1.15M shares traded or 272.94% up from the average. Quotient Limited (NASDAQ:QTNT) has declined 24.44% since May 18, 2017 and is downtrending. It has underperformed by 35.99% the S&P500.

Quotient Limited, a commercial-stage diagnostics company, develops, makes, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company has market cap of $246.63 million. The firm is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. It currently has negative earnings. It also develops, makes, and commercializes conventional reagent products for blood grouping, including antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping.

More important recent Quotient Limited (NASDAQ:QTNT) news were published by: Nasdaq.com which released: “Quotient Limited Reports Commencement of EU Blood Grouping Field Trial” on May 17, 2018, also Streetinsider.com published article titled: “Quotient (QTNT) Commences EU Blood Grouping Field Trial”, Streetinsider.com published: “Pre-Open Movers 05/18: (QTNT) (AFSI) (CERN) Higher; (AGRX) (ARQL) (CPB) Lower (more…)” on May 18, 2018. More interesting news about Quotient Limited (NASDAQ:QTNT) was released by: Globenewswire.com and their article: “Quotient Limited to Report Fourth Quarter and Fiscal Full Year 2018 Financial Results and Host Conference Call” with publication date: May 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.